home / stock / wxibf / wxibf news


WXIBF News and Press, Wuxi Biologics Cayman Inc From 08/25/21

Stock Information

Company Name: Wuxi Biologics Cayman Inc
Stock Symbol: WXIBF
Market: OTC

Menu

WXIBF WXIBF Quote WXIBF Short WXIBF News WXIBF Articles WXIBF Message Board
Get WXIBF Alerts

News, Short Squeeze, Breakout and More Instantly...

WXIBF - 5 Top Pharmaceutical ETFs

The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...

WXIBF - China Regulatory Shock - What's Next For Internet Stocks

It was an excruciating week of a severe emotional storm with the share prices undergoing a rollercoaster ride. A deluge of news, speculations, and commentaries overwhelmed the mind. The massive and synchronized sell-off of Chinese equities was akin to a Golden Slam for the critics. It...

WXIBF - Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures

Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as "...

WXIBF - China Healthcare: A Rediscovered Sector Keeps Its Momentum

Healthcare was the second-best performing sector in China in 2020. The immediate healthcare needs stemming from the pandemic, together with the emergence of green shoots in biotech innovation, paved the way for a landmark year in the development of China’s healthcare system. ...

WXIBF - Alibaba's Bottoming Despite Odds, Baidu's Dog Days Are Over

In a positive start to 2021, the representative ETFs of Chinese companies rallied by a wide margin over with their respective U.S. counterparts. The outperformance came despite the dark cloud of investment bans on Alibaba and Tencent, as well as usage prohibition of certain Chine...

WXIBF - Week In Review: BeiGene Plans $2.5 Billion IPO On Shanghai Star Exchange

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors or multiple myeloma. LianBio, a P...

WXIBF - Week In Review: Suzhou's Ascentage Pharma Stages $53 Million IPO In Hong Kong

Deals and Financings Ascentage Pharma of Suzhou completed a $53 million Hong Kong IPO, pricing the offering at the top end of the indicated range with a market capitalization of almost $890 million. The company is developing therapeutics for cancer based on its expertise in protein-protein i...

Previous 10 Next 10